We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$97.2M
AUM Growth
+$5.62M
Cap. Flow
+$348K
Cap. Flow %
0.36%
Top 10 Hldgs %
67.75%
Holding
59
New
8
Increased
8
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
WINT
Windtree Therapeutics Inc
WINT
+$8.21M
2
NXTM
NxStage Medical Inc.
NXTM
+$1.5M
3
MTEM
Molecular Templates, Inc.
MTEM
+$1.28M
4
ACHV icon
Achieve Life Sciences
ACHV
+$895K
5
PCYC
PHARMACYCLICS INC
PCYC
+$789K

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$2.74M
2
CRIS icon
Curis
CRIS
+$1.3M
3
KBIO
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
+$1.13M
4
BEAT
BioTelemetry, Inc.
BEAT
+$867K
5
RXII
GALENA BIOPHARMA INC COM
RXII
+$855K

Sector Composition

Rank Sector Weight
1 Healthcare 73.36%
2 Miscellaneous 25.34%
3 Financials 1.3%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WINT
1
DELISTED
Windtree Therapeutics Inc
WINT
$12.8M 13.2%
407,053
+262,364
+181% +$8.21M
PCYC
2
DELISTED
PHARMACYCLICS INC
PCYC
$11.5M 11.83%
108,628
+6,500
+6% +$789K
ATRC icon
3
AtriCure
ATRC
$2.47B
$8.53M 8.78%
456,701
-21,000
-4% -$305K
STXS icon
4
Stereotaxis
STXS
$145M
$6.29M 6.48%
2,173,123
+1,218
+0.1% +$3.42K
GIVN
5
DELISTED
GIVEN IMAGING LTD
GIVN
$4.7M 4.84%
156,320
– –
NVDQ
6
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.68M 4.82%
284,041
– –
PLX icon
7
Protalix BioTherapeutics
PLX
$205M
$4.58M 4.72%
117,844
– –
PODD icon
8
Insulet
PODD
$10.1B
$4.51M 4.64%
121,481
-3,500
-3% -$129K
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$3.84M 3.95%
384,154
+132,500
+53% +$1.5M
AMPE
10
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$3.04M 3.12%
1,419
– –
MACK
11
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.83M 1.88%
43,526
+20,501
+89% +$594K
BEAT
12
DELISTED
BioTelemetry, Inc.
BEAT
$1.71M 1.76%
215,645
-92,920
-30% -$867K
VXRT
13
DELISTED
Vaxart
VXRT
$1.37M 1.41%
29,745
+11,367
+62% +$500K
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
$1.31M 1.35%
+1,700
New +$1.28M
SPNC
15
DELISTED
Spectranetics Corp
SPNC
$1.31M 1.35%
52,362
– –
RIOT icon
16
Riot Platforms
RIOT
$7.13B
$1.26M 1.3%
73,750
– –
BSTC
17
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.12M 1.15%
51,692
– –
ELOS
18
DELISTED
Syneron Medical Ltd
ELOS
$1.12M 1.15%
90,947
– –
CRDC
19
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.04M 1.07%
106,347
– –
XNPT
20
DELISTED
XENOPORT, INC.
XNPT
$1.02M 1.05%
177,362
-13,900
-7% -$75.2K
ACHV icon
21
Achieve Life Sciences
ACHV
$834M
$928K 0.96%
+51
New +$895K
CUTR
22
DELISTED
Cutera, Inc.
CUTR
$903K 0.93%
88,694
– –
HSTO
23
DELISTED
Histogen Inc. Common Stock
HSTO
$875K 0.9%
678
+100
+17% +$160K
JNJ icon
24
Johnson & Johnson
JNJ
$646B
$861K 0.89%
9,400
– –
OCRX
25
DELISTED
Ocera Therapeutics, Inc.
OCRX
$821K 0.85%
63,223
+55,329
+701% +$517K
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, DAFNA Capital Management held 59 positions worth $97.2M, up 6.1% from $91.5M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

DAFNA Capital Management's Q4 2013 filing shows 8 new, 8 increased, 8 reduced and 10 closed positions. Its largest new stake was Molecular Templates, Inc.: 1,700 shares worth $1.31M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $2.74M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q4 2013 buy was Molecular Templates, Inc.: 1,700 shares worth $1.31M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q4 2013, an estimated $8.21M increase.
  • DAFNA Capital Management's biggest Q4 2013 reduction was Curis, cutting an estimated $1.3M.
  • DAFNA Capital Management fully exited Ariad Pharmaceuticals Inc in Q4 2013, selling an estimated $2.74M.
  • DAFNA Capital Management's ten largest holdings make up 68% of its $97.2M portfolio in Q4 2013.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q4 2013.
  • DAFNA Capital Management's portfolio value rose 6.1% quarter-over-quarter to $97.2M.

Based on DAFNA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.